Suggested remit: To appraise the clinical and cost effectiveness of ONS-5010 within its marketing authorisation for treating wet age-related macular degeneration.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
| Process |
Cost Comparison Standard
|
| ID number |
6320
|
Provisional Schedule
| Expected publication |
04 December 2024 |
Project Team
| Project lead |
Louise Jafferally |
Email enquiries
| External Assessment Group |
Southampton Health Technology Assessment Centre (SHTAC), University of Southampton |
Stakeholders
| Companies sponsors |
Outlook Therapeutics Limited (bevacizumab gamma) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
Macular Society |
| Professional groups |
College of Optometrists |
| |
Royal College of Ophthalmologists |
| |
Royal College of Physicians |
| Associated public health groups |
None |
| Comparator companies |
Bayer (aflibercept) (confidentiality agreement signed, participating) |
| |
Biogen (ranibizumab) (confidentiality agreement signed, participating) |
| |
Roche (faricimab) (confidentiality agreement signed, participating) |
| |
Genus Pharmaceuticals (ranibizumab) (confidentiality agreement not signed, not participating) |
| |
Novartis (ranibizumab, brolucizumab) (confidentiality agreement not signed, not participating) |
| |
Teva UK (ranibizumab) (confidentiality agreement not signed, not participating) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
None |
|
Date
|
Update
|
|
31 October 2024 - 14 November 2024
|
Final draft guidance |
|
20 June 2024
|
Invitation to participate |
|
01 March 2024 - 02 April 2024
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6320 |
|
01 January 2024
|
In progress. DHSC referral received |
|
23 November 2022
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual